Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.

You may also be interested in...



Deals Of The Week’s Takeaway From PSA: Optimism With Aches

The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.

Two Days, Two Deals: AbbVie To Partner (Again) With Galapagos In Cystic Fibrosis

AbbVie’s busy week continued when it unveiled a collaboration with Galapagos in cystic fibrosis Sept. 24, a day after it announced an inflammatory disease tie-up with Ablynx. AbbVie and Galapagos already are partnered under a 2012 deal in rheumatoid arthritis and Crohn’s disease.

Abbott Adds To Renal Pipeline In Deal With Action Pharma

For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel